Investor Alert: Argentina Loaded With "White Gold" Opportunity
Experts expect the global lithium market to grow by 500% due to the explosion of electric vehicles and green energy. And one small-cap company just snagged a large lithium deposit in a renowned South American location.
Read about this once-in-a-lifetime opportunity
Susan Molineaux, insider at Calithera Biosciences
Susan Molineaux Insider Alerts

Get notified the next time Susan Molineaux buys or sells Calithera Biosciences stock. Enter your email address below to get our daily insider buying and selling report.

Susan Molineaux Insider Information

Dr. Molineaux is the co-founder, President and CEO of Calithera Biosciences, a start-up company that commenced operations in June of 2010. Prior to starting Calithera, Dr. Molineaux was a co-founder of Proteolix and served as the CSO for two years before becoming President and CEO of the company. Proteolix was acquired by Onyx Pharmaceuticals in November 2009. Prior to joining Proteolix, Dr. Molineaux was Vice President of Biology at Rigel Pharmaceuticals from 2000 to 2003. Before that, she was Vice President of Biology at Praelux, and from 1994 through 1999, Dr. Molineaux served as Vice President of Drug Development at Praecis Pharmaceuticals. From 1989 until 1994 she was a scientist in the immunology group at Merck, in Rahway, NJ.

Education:
B.S. in Biology from Smith College
Ph.D. in Molecular Biology from Johns Hopkins University
Postdoctoral fellowship at Columbia University

What is Susan Molineaux's salary?

As the CEO of Calithera Biosciences, Inc., Dr. Molineaux earned a total compensation package of $3,620,571.00 in 2020. Dr. Molineaux earned a salary of $569,250.00, a bonus of $222,008.00, options awards of $2,813,619.00, and other compensation of $15,694.00.

How do I contact Susan Molineaux?

The corporate mailing address for Dr. Molineaux and other Calithera Biosciences executives is 343 OYSTER POINT BLVD. SUITE 200, SOUTH SAN FRANCISCO CA, 94080. Calithera Biosciences can also be reached via phone at (650) 870-1000 and via email at [email protected]

Has Susan Molineaux been buying or selling shares of Calithera Biosciences?

During the last ninety days, Susan Molineaux has bought $85,000.00 of Calithera Biosciences stock. Most recently, on Wednesday, November 10th, Susan Molineaux bought 100,000 shares of Calithera Biosciences stock. The stock was acquired at an average cost of $0.85 per share, with a total value of $85,000.00.

Who are Calithera Biosciences' active insiders?

Calithera Biosciences' insider roster includes Susan Molineaux (CEO), and Keith Orford (Director).

Are insiders buying or selling shares of Calithera Biosciences?

During the last twelve months, Calithera Biosciences insiders bought shares 1 times. They purchased a total of 100,000 shares worth more than $85,000.00. During the last twelve months, insiders at the biotechnology company sold shares 3 times. They sold a total of 102,447 shares worth more than $100,609.60. The most recent insider tranaction occured on November, 11th when Director Keith Orford sold 48,190 shares worth more than $42,407.20. Insiders at Calithera Biosciences own 11.6 % of the company.

Information on this page was last updated on 11/11/2021.

Susan Molineaux Insider Trading History at Calithera Biosciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/10/2021Buy100,000$0.85$85,000.00View SEC Filing Icon  
6/25/2019Buy51,600$3.88$200,208.00View SEC Filing Icon  
See Full Table

Susan Molineaux Buying and Selling Activity at Calithera Biosciences

This chart shows Susan Molineaux's buying and selling at Calithera Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Calithera Biosciences Company Overview

Calithera Biosciences logo
Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on discovering and developing small molecule drugs that target novel and critical metabolic pathways in tumor and cancer-fighting immune cells. It offers programs such as Pipeline, Glutaminase Inhibitor, and Arginase Inhibitor. The company was founded by James A. Wells and Susan M. Molineaux on March 9, 2010 and is headquartered in South San Francisco, CA.
Read More

Today's Range

Now: $0.84
Low: $0.84
High: $0.92

50 Day Range

MA: $1.67
Low: $0.82
High: $2.40

2 Week Range

Now: $0.84
Low: $0.81
High: $6.19

Volume

861,972 shs

Average Volume

3,938,597 shs

Market Capitalization

$62.87 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.57
One Pot Stock Could Skyrocket With Looming Interstate Sales
A new bill in Congress would decriminalize marijuana nationally by removing cannabis from the federal government’s list of controlled substances. The law would also allow one established Seattle cannabis company to market across state lines for the first time – potentially setting off a bidding war that could blast this stock into the stratosphere!
Find Out Why This Could Be the #1 Pot Stock